[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colonic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colonic-neoplasms":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,59,91,112,150,171,193,226,254,275,305,329],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100584158","phase-1-anti-mesothelin-tnaivescm-hyp218-tnhyp218-car-t-cells-in-participants-with-mesothelin-expressing-solid-tumors-including-mesothelioma-100584158",false,"NCT06885697","Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria. For this protocol, treatment initiation is defined as the first day of lymphodepleting chemotherapy.\n\n* Participant must have unresectable, locally advanced, or metastatic, or recurrent mesothelioma and other mesothelin expressing solid tumors. For participants with mesothelioma only those with epithelioid or biphasic histology (with \\>80% epithelioid component) will be eligible. The diagnosis will be confirmed by the Laboratory of Pathology, CCR, NCI.\n* Participant must have progressed on at least one FDA-approved systemic therapy considered standard of care for their tumor type. There is no limit on the number of prior treatment regimens. Note: Given the aggressive nature of pancreatic cancer, otherwise eligible individuals with this cancer type can undergo leukapheresis before or while they are getting their frontline treatment as long as they meet all other inclusion criteria. However, TNhYP218 CAR T cells will only be administered after progression on first line standard of care therapy.\n* Participant must have at least 1 measurable lesion by RECIST version 1.1.\n* Tumor must have MSLN positivity of 2+ to 3+ in \\>= 50% cancer cells by immunohistochemistry on freshly collected biopsy or archival tissue.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate organ and marrow function as defined below:\n\nSystem: Laboratory Value\n\nHematological\n\n* Hemoglobi: \\>=9 g\u002FdL(a)\n* absolute neutrophil count: \\>=1,500\u002FmcL\n* platelets: \\>=100,000\u002FmcL\n\nHepatic\n\n* total bilirubin: \\\u003C=2.5 X institutional ULN OR direct bilirubin ULN for participants with total bilirubin levels \\>1.5 X ULN\n* AST and ALT \\\u003C= 2.5 X institutional ULN (\\\u003C= 5 X ULN for participants with liver metastases)\n\nRenal\n\n* Creatinine OR: \\\u003C=1.5 X ULN OR\n* Calculated(b) creatinine clearance (GFR can also be used in place of creatinine or CrCl) \\>= 50 mL\u002Fmin for participant with creatinine levels \\> 1.5 X institutional ULN\n\nCoagulation\n\n* International normalized ratio (INR) OR prothrombin time (PT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n\nALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n\n1. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.\n2. Creatinine clearance (CrCl) should be calculated per institutional standard.\n\n   * Normal cardiac ejection fraction (\\>= 45% by echocardiogram) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram.\n   * Room air oxygen saturation of 90% or greater.\n   * Treatment-related toxicities from prior treatments must be resolved to \\\u003C= grade 2.\n   * Participants with CNS metastases, leptomeningeal disease or carcinomatous meningitis are eligible if they are asymptomatic, have completed their treatment for CNS disease and have recovered from the acute effects of radiation therapy or surgery prior to study entry. Participants must have radiographically stable CNS disease without associated edema at least three months prior to study entry. Additionally, participants have had to have discontinued corticosteroid treatment or non-prophylactic antiseizure medications for these metastases at least four weeks prior to study entry.\n   * Participants of child-bearing potential and participants who can father children must agree to use highly effective contraception or abstinence.\n   * Participants who are nursing or plan to nurse a child must agree to discontinue\u002Fpostpone nursing for the duration of study therapy and for 12 months after the administration of the cell product or for 4 months from the time no evidence of persistence\u002Fgene modified cells is documented in the participant s blood.\n   * Ability of participant to understand and the willingness to sign a written informed consent document.\n\n   EXCLUSION CRITERIA:\n\n   An individual who meets any of the following criteria will be excluded from participation in this study:\n   * Prior systemic therapy, an investigational therapy, radiation, and\u002For surgery within 14 days prior to leukapheresis and 21 days prior to lymphodepleting chemotherapy.\n   * Prior administration of anti-PD-1 or anti-PD-L1 antibodies or other agents that in the opinion of the PI can stimulate immune activity and interfere with an infusion of CAR-T cells within 8 weeks prior to treatment initiation.\n   * Participants with any form of primary immunodeficiency (e.g. severe combined immunodeficiency).\n   * Participants with active or history of autoimmune or immune mediated disease such as multiple sclerosis, lupus, inflammatory bowel disease, rheumatoid arthritis, or small vessel vasculitis. NOTE: Participants with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.\n   * History of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine.\n   * Therapeutic doses of systemic corticosteroid therapy within 14 days prior to treatment initiation. Physiological doses of steroids (up to 5mg\u002Fday of prednisolone or equivalent) are allowed. Corticosteroid creams, ointments, and eye drops are allowed.\n   * Participants with lung fibrosis, inflammatory lung disease or evidence of pneumonitis on baseline imaging studies or medical history of these disorders.\n   * Participant has any other prior or concurrent malignancy with the following exceptions:\n\n     * Adequately treated basal cell or squamous cell carcinoma\n     * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 12 months prior to initiation of study therapy.\n     * Treated non-melanoma skin cancer.\n     * Stage 0 or 1 melanoma completely resected at least 12 months prior to initiation of study therapy.\n     * Successfully treated organ-confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy.\n     * A primary malignancy which has been completely resected and in complete remission for \\>= 5 years.\n   * Electrocardiogram showing a QTc interval \\> 450 msec in males and \\> 470 msec in females (\\> 80 msec for participants with bundle branch block). Either Fridericia s or Bazett s formula may be used to correct the QT interval.\n   * Participant has active infection with HIV, hepatitis B virus, HCV, or HTLV as defined below:\n\n     * Positive serology for HIV, HTLV-1, or HTLV-2.\n     * Active hepatitis B infection as demonstrated by test for hepatitis B surface antigen. Participants who are hepatitis B surface antigen negative but are hepatitis B core antibody positive must have undetectable hepatitis B DNA and receive prophylaxis against viral reactivation.\n     * Active hepatitis C infection as demonstrated by hepatitis C RNA test. Participants who are HCV antibody positive will be screened for HCV RNA by any reverse transcription PCR or branched DNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.\n   * Participant is pregnant or intends to be pregnant during the required period of contraception for participants of childbearing potential.\n   * Participants who received live or attenuated vaccine or virus-based vaccine within 30 days before initiation of treatment initiation\n   * Participants with a history of seizure disorder unless due to now treated metastatic lesions.\n   * Ongoing uncontrolled intercurrent illness, including but not limited to ongoing or active infection, that would impact participant safety or limit compliance with study requirements.","ALL","18 Years","120 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nMesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN.\n\nObjective:\n\nTo test a new treatment (TNhYP218 CAR T cells) in people with solid tumors including mesothelioma.\n\nEligibility:\n\nPeople aged 18 and older with solid tumors including mesothelioma that returned or spread after standard treatment.\n\nDesign:\n\nParticipants will be screened. A small piece of tissue will be cut from a tumor (biopsy). The sample will be tested to see if it has enough MSLN.\n\nParticipants will undergo leukapheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein.\n\nParticipant s T cells will be modified in a lab to produce TNhYP218 CAR T cells.\n\nParticipants will enter the hospital. For 7 days, they will receive drugs to prepare their bodies for the study treatment.\n\nTNhYP218 CAR T cells will be administered into a vein. Participants will remain in the hospital for at least 7 more days.\n\nAfter discharge, participants will have follow-up visits for 5 years. These visits may include imaging scans, blood and heart tests, and a new biopsy.\n\nLong-term follow-up will continue another 10 years....",[27,28,29,30,31,32,33,34],"Mesothelioma","Neoplasms","Stomach Neoplasms","Pancreatic Neoplasms","Ovarian Neoplasms","Lung Neoplasms","Thymus Neoplasms","Colonic Neoplasms",[36,37,38,39,40,41,42,43,44,45],"Peritoneal Mesothelioma","Thymic Carcinoma","Colon Cancer","Gastric Cancer","Lung Cancer","Ovarian Cancer","Pancreatic Cancer","mesothelin expressing solid tumors","CAR T cell therapy","Gene Therapy","RECRUITING","2026-06-16",{"date":49,"type":50},"2026-06-17","ACTUAL",{"date":52,"type":50},"2025-07-08",{"date":54,"type":21},"2044-06-01",{"name":56,"class":57},"National Cancer Institute (NCI)","NIH",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":58},"100617159","laparoscopic-versus-open-surgery-for-colon-cancer-with-visceral-obesity-100617159","NCT07314996","Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity","A Randomized Controlled Trial of Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity","LOVO","Inclusion Criteria:\n\n1. Body Roundness Index (BRI) ≥ 5.0, with no laparoscopic surgery contraindications as assessed by the surgeon;\n2. Pathologically confirmed colon adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma;\n3. Tumor lower edge \\> 12 cm from the anus as measured by colonoscopy, and the tumor lower edge not directly palpable by digital rectal examination;\n4. Single primary lesion;\n5. Aged 18 (inclusive) to 75 (inclusive) years;\n6. Clinical stage T3\u002F4Nany or T1-4N+ on chest non-contrast CT and abdominal enhanced CT, no distant metastasis, and resectable as judged by the surgeon;\n7. Treatment-naive, no prior anti-tumor treatment;\n8. Completed blood routine, liver and kidney function tests, carcinoembryonic antigen (CEA), and carbohydrate antigen 199 (CA199) before randomization, with American Society of Anesthesiologists (ASA) score ≤ III;\n9. Patient able to understand the study protocol and willing to participate in the study.\n\nExclusion Criteria:\n\n1. Height and waist circumference data are unavailable;\n2. Hereditary colorectal cancer (Lynch syndrome or Familial Adenomatous Polyposis \\[FAP\\]);\n3. History of previous malignant neoplasm, with the exception of basal cell carcinoma\u002Fpapillary thyroid carcinoma\u002Fvarious types of in situ cancers\u002Fmicro-invasive early-stage lung cancer;\n4. Acute exacerbation of major organ diseases (such as, but not limited to, COPD, coronary heart disease, and renal insufficiency) and\u002For severe acute infectious diseases (such as, but not limited to, hepatitis, pneumonia, and myocarditis);\n5. The tumor presents with obstruction or is at high risk of obstruction, and\u002For there is bleeding and\u002For perforation, which may necessitate emergency surgery;\n6. Pregnancy or breastfeeding;\n7. Inability to undergo contrast-enhanced CT scan;\n8. Additional surgery after EMR or ESD;\n9. Patients with unremitted severe mental illness, moderate or above cognitive impairment (MMSE ≤ 23 points), or those who have been hospitalized due to mood disorders in the past year or have unstable antipsychotic medication;\n10. Patients with enlarged mesenteric root lymph nodes detected by preoperative CT or intraoperative exploration and suspected metastasis, or suspected metastasis in organs such as peritoneum or liver detected by intraoperative exploration;\n11. Patients with a history of major abdominal surgery and severe adhesions precluding laparoscopic surgery upon laparoscopic exploration.","75 Years",{"count":69,"type":21},664,[71],"NA","This study aims to elucidate whether there is a difference in long-term prognosis between laparoscopic surgery and open surgery in colon cancer patients with visceral obesity.",[34],[75,76,77,78,79,80],"laparoscopic surgery","open surgery","Body Round Index (BRI)","complete mesocolic excision","oncologic outcome","specimen quality","2026-06-01",{"date":83,"type":50},"2026-06-03",{"date":85,"type":50},"2026-01-18",{"date":87,"type":21},"2033-12-31",{"name":89,"class":90},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100121127","evaluation-of-stool-based-markers-for-the-early-detection-of-colorectal-cancers-and-adenomas-100121127","NCT00843375","Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas","Inclusion Criteria:\n\n* Willing to sign informed consent\n* Able to physically tolerate removal of up to 60 ml of blood\n* Adults at least 18 years old\n* Willing to collect 1-2 stool samples and prepare a Fecal Immunochemical Test (FIT)\n* Pregnant or nursing women who otherwise meet the eligibility criteria may participate\n* Subjects with one of the following:\n\n  * Colorectal adenocarcinoma-not treated and in colon at time of stool collection (CRC bin)\n  * Adenoma-pathologically confirmed adenoma present in colon at time of stool collection (Adenoma Bin)\n  * Higher Risk Non-neoplastic Bin\n\n    * Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy\n    * Subjects with a personal history of CRC (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy\n    * Any family history of CRC (1st degree relative)\n    * Current positive screening stool test for blood, for DNA or for both within 12 months with no follow-up intervention.\n  * Average Risk, Non-neoplastic Bin\n\n    * No history or current finding of any colorectal neoplasia including CRC, adenomas, sessile serrated adenomas and no family history of CRC.\n    * Subjects who had CRC that was successfully treated at least three years ago may be considered eligible for the adenoma bin if their polyps are adenomas and there is no evidence of CRC, or for the higher risk non-neoplastic bin as noted above.\n    * Subjects whose screening colonoscopy shows any of these types of polyps may be included in the non-neoplastic or the higher risk non-neoplastic bin if they meet the other criteria noted above.\n\n      * Hyperplastic polyps\n      * Benign mucosal polyps\n      * Polypoid granulation tissue\n      * Prolapsed mucosal polyps\n      * Inflammatory polyp\n      * Transitional mucosal polyp\n      * Lipoma\n      * Gangleoneuroma\n      * Neuroma\n      * Hamartomatous polyp\n\nExclusion Criteria:\n\n* Cancer patients who have had any surgery, radiation, or chemotherapy for their current colorectal cancer prior to collecting the baseline samples\n* History of or clinically active Inflammatory Bowel Disease\n* Known HNPCC or FAP\n* Inability to provide informed consent.\n* Other active malignancy within 3 years of enrollment except any of the following:\n\n  * Squamous cell carcinoma of the skin\n  * Basal cell carcinoma of the skin\n  * Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only. (Excluded if had pelvic radiation)\n  * Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery\n* Patients on active chemotherapy or radiation treatment for any purpose\n* Known HIV or chronic active viral hepatitis\n* Women who are pregnant\n* CT colonography (virtual colonoscopy) patients",{"count":98,"type":21},1200,"OBSERVATIONAL","Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy.\n\nThe purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.",[34],"2026-05-07",{"date":104,"type":50},"2026-05-11",{"date":106,"type":50},"2019-08-07",{"date":108,"type":21},"2028-03",{"name":110,"class":90},"University of Michigan Rogel Cancer Center",13,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":149},"100504966","phase-3-study-of-perioperative-dostarlimab-in-participants-with-untreated-t4n0-or-stage-iii-dmmrmsi-h-resectable-colon-cancer-100504966","NCT05855200","Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer","A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer","Inclusion Criteria:\n\n* Has untreated pathologically confirmed colon adenocarcinoma\n* Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III\n* Has radiologically evaluable disease\n* Has a tumor demonstrating the presence of either dMMR status or MSI-H\n\nExclusion Criteria:\n\n* Has distant metastatic disease.\n* Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer\n* Has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent\u002Femergent surgery at the time of screening. Participants with a history of colonic obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning ileostomy or colostomy). Patients with a history of colonic obstruction in the context of current colon cancer diagnosis and treated with colonic stents are not eligible.\n* Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to randomization\n* Has any history of interstitial lung disease or pneumonitis and\u002For history of radiation induced enteritis.\n* Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice\n* Has a history of allogenic stem cell transplantation or organ transplantation\n* Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention\n* Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study\n* Has a history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of FOLFOX or CAPEOX",{"count":120,"type":21},892,[122],"PHASE3","The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair\u002F microsatellite instability high (dMMR\u002FMSI-H) colon cancer.",[34,125],"Neoplasms, Colon",[127,128,129,130,131,132,133,38,134,135,136,137,138],"JEMPERLI","Dostarlimab","dostarlimab-gxly","TSR-042","GSK4057190A","FOLFOX","CAPEOX","Resectable colon cancer","dMMR\u002FMSI","Perioperative","Neoadjuvant","Adjuvant","2026-01-22",{"date":141,"type":50},"2026-01-23",{"date":143,"type":50},"2023-08-01",{"date":145,"type":21},"2031-03-27",{"name":147,"class":148},"GlaxoSmithKline","INDUSTRY",266,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":58},"100606317","strategies-for-optimizing-a-mailed-fit-program-in-appalachia-100606317","NCT07173985","Strategies for Optimizing a Mailed FIT Program in Appalachia","Inclusion Criteria:\n\n* Resident of an Appalachian county\n* Medical visit at a participating health system in the past two years\n* Average-risk for colorectal cancer\n* Not currently within colorectal cancer screening guidelines\n\nExclusion Criteria:\n\n\\-","45 Years","74 Years",{"count":159,"type":21},500,[71],"The proposed study is examining strategies for optimizing mailed fecal immunochemical test (FIT) programs. In doing so, it will assess the efficacy of two promising strategies, FIT kit materials and patient navigation delivery mode. These strategies may help to improve colorectal cancer screening rates.",[34],"2026-01-21",{"date":139,"type":50},{"date":166,"type":50},"2026-01-20",{"date":168,"type":21},"2028-07-31",{"name":170,"class":90},"Ohio State University Comprehensive Cancer Center",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100498660","adaptive-randomization-of-aerobic-exercise-during-chemotherapy-in-colon-cancer-100498660","NCT05773144","Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer","ACTION","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed stage II or III colon cancer\n* Completed surgical resection with curative intent\n* Plan to initiate chemotherapy\n* Engage in \\\u003C60 minutes per week of moderate- to vigorous-intensity structured aerobic exercise\n* No planned major surgery during the study period\n* Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire\n* Can walk 400 meters\n* Can read and speak English\n* Ability to provide written informed consent\n* Provide written approval by qualified healthcare professional\n* Willing to be randomized\n\nExclusion Criteria:\n\n* Evidence of metastatic colon cancer\n* Concurrently actively treated other (non-colon) cancer\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks\n* Currently participating in another study with competing outcomes\n* Any other condition that, in the opinion of the investigator, would preclude participation or successful compliance with the protocol\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",{"count":179,"type":21},219,[71],"To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.",[34],"2026-01-05",{"date":185,"type":50},"2026-01-07",{"date":187,"type":50},"2023-06-01",{"date":189,"type":21},"2027-05-01",{"name":191,"class":90},"AdventHealth Translational Research Institute",3,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":203,"conditions":204,"keywords":210,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":58},"100422394","endoscopic-resection-of-gastrointestinal-neoplasms-100422394","NCT04780256","Endoscopic Resection of Gastrointestinal Neoplasms","Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract","Inclusion Criteria:\n\n* 18 years or older\n* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\n* age under 18\n* inability to provide informed consent","100 Years",{"count":202,"type":21},2000,"The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.",[205,206,207,34,208,209],"Endoscopic Mucosal Resection","Endoscopic Submucosal Dissection","Gastric Neoplasm","Esophageal Neoplasms","Duodenal Neoplasms",[211,212,213,214,215],"Endoscopic mucosal resection (EMR)","Endoscopic submucosal dissection (ESD)","Endoscopic full thickness resection (EFTR)","Colorectal ESD","Colorectal EMR","2025-09-30",{"date":218,"type":50},"2025-10-03",{"date":220,"type":50},"2021-03-15",{"date":222,"type":21},"2025-12",{"name":224,"class":225},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":67,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":58},"100603091","phase-3-neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer-100603091","NCT07132008","Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","Prospective, Multicenter, Randomized Trial of Neoadjuvant Capecitabine and Oxaliplatin (CAPOX) Plus Tislelizumab Versus CAPOX in Microsatellite Stable High-risk Locally Advanced Colon Cancer","Inclusion Criteria:\n\n* Age ≥18 years old and ≤75 years old.\n* Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma.\n* The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination.\n* Enhanced CT stage T4 or T1-4 N+ without multiple primary tumors or distant metastasis.\n* The Eastern Cooperative Oncology Group physical status score is 0-1.\n* Life expectancy is expected to be more than 1 year.\n* First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications.\n* Appropriate organ function is defined as follows: Hemoglobin level ≥ 60g\u002FL, Neutrophil count ≥ 1.5×10\\^9\u002FL, Platelet count ≥ 75×10\\^9\u002FL, Serum total bilirubin ≤ 1.5× the upper limit of normal (UNL), Aspartate aminotransferase (AST) ≤ 2× UNL, Alanine aminotransferase (ALT) ≤ 3× UNL, Serum creatinine ≤ 1.5× UNL.\n* Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent.\n\nExclusion Criteria:\n\n* Enhanced CT stage (T1-3N0M0)\n* Multifocal colorectal cancer.\n* CT or MRI in the mid-sagittal plane shows that the lower border of the tumor is below the line connecting the sacrococcygeal promontory and the upper border of the pubic symphysis.\n* Tumor obstruction or high risk of obstruction, bleeding, and\u002For perforation requiring emergency surgery or stent placement.\n* Cannot tolerate chemotherapy or immunotherapy, such as but not limited to bone marrow suppression.\n* History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers.\n* Acute exacerbation of important organ diseases (such as but not limited to chronic obstructive pulmonary disease, coronary heart disease, and renal insufficiency) and\u002For severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), American Society of Anesthesiologists score \\> 3 points.\n* Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol.\n* Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy.\n* Continuous use of glucocorticoids for more than 3 days within 1 month prior to signing the informed consent form, or having comorbidities requiring the use of glucocorticoid therapy.\n* Unable to undergo enhanced CT examination\n* Pregnancy or lactation.\n* Refused to participate in this study.\n* Other situations in which the researcher deems unsuitable for this study.",{"count":234,"type":21},94,[122],"Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.",[34,238,239],"Neoadjuvant Therapy","Immune Checkpoint Inhibitors",[241,242,243],"Colon cancer","Neoadjuvant chemotherapy","PD-1 inhibitor","NOT_YET_RECRUITING","2025-08-13",{"date":247,"type":50},"2025-08-20",{"date":249,"type":21},"2025-10-01",{"date":251,"type":21},"2030-09-30",{"name":253,"class":90},"First Affiliated Hospital of Guangxi Medical University",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":58},"100499913","effects-of-aerobic-exercise-on-skeletal-muscle-remodeling-in-colorectal-cancer-100499913","NCT05789433","Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer","RESTORE","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed stage I, II, or III colon or rectal cancer\n* Completed surgical resection with curative intent\n* Completed other cancer-directed treatments\n* Engage in \\\u003C150 minutes per week of moderate- to vigorous-intensity structured endurance exercise\n* No planned major surgery during the study period\n* Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire\n* Ability to provide written informed consent\n* Provide written approval by a qualified healthcare professional\n* Willing to be randomized\n\nExclusion Criteria:\n\n* Evidence of metastatic or recurrent colorectal cancer\n* Concurrently actively treated other (non-colorectal) cancer\n* Scheduled to receive other postoperative cancer-directed treatment(s)\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks\n* Currently participating in another study with competing outcomes\n* Contraindications to magnetic resonance imaging\n* Any dietary condition or restriction that would limit tolerance of a mixed meal challenge\n* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol\n* Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol",{"count":262,"type":21},70,[71],"The goal of this clinical trial is to quantify the effects of aerobic exercise training compared to attention control on intermuscular adipose tissue in colorectal cancer survivors.",[34,266],"Rectal Neoplasms","2025-07-01",{"date":269,"type":50},"2025-07-03",{"date":271,"type":50},"2023-05-01",{"date":273,"type":21},"2027-03-01",{"name":191,"class":90},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":283,"sex":16,"minAge":156,"maxAge":157,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":293,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":58},"100576976","artificial-intelligence-assisted-colonoscopy-in-colorectal-cancer-screening-in-a-general-hospital-100576976","NCT06792292","Artificial Intelligence-Assisted Colonoscopy in Colorectal Cancer Screening in a General Hospital","Real-World Experience of Artificial Intelligence-Assisted Colonoscopy in Colorectal Cancer Screening in a General Hospital: A Single-Center Cohort Phase IV Study","Delta-AI","Inclusion criteria:\n\n* Patient (woman or man) candidate for a screening colonoscopy - Age: 45 to 74 years included\n* Absence of inflammatory bowel disease\n* Absence of significant digestive symptoms indicating colonoscopy (i.e. screening is the only indication for the examination)\n* Patient able to understand the concept of the study and agreeing to participate\n\nExclusion criteria:\n\n* Patient outside the inclusion age\n* All exclusion criteria for a colonoscopy.\n* The indication for colonoscopy is not simple screening; for example, assessment of anemia, rectal bleeding, weight loss or abdominal pain.\n* Patient's refusal to participate, or patient's inability to understand the study concept\n* Any patient with major psychological or psychiatric disorders.",true,{"count":285,"type":21},765,[71],"Cancer can develop in the colon, or large bowel. Examination of the colon with a tube fitted with a camera is called a colonoscopy.\n\nColonoscopy allows detection of small growths in the colon, called \"polyps\". Polyps can often be removed during colonoscopy. Some of these polyps are called adenomas and can become cancer after several years.\n\nA good colonoscopy aims to find and take out as many of these polyps as possible.\n\nA quality indication of colonoscopy is the \"adenoma detection rate\" (ADR). It should be high, meaning many polyps are detected and taken out.\n\nNew artificial intelligence devices to assist colonoscopy seem to increase the ADR, and maybe help prevent cancer even better than normal colonoscopy.\n\nThe goal of this clinical trial is to compare the ADR when using standard colonoscopy to the ADR with artificial intelligence (AI)-assisted colonoscopy.",[289,290,34,291,292],"Artificial Intelligence","Colonic Adenoma","Colonic Polyp","Colonoscopy",[294,295],"colo-rectal cancer screening","artificial intelligence assisted colonoscopy","2025-01-20",{"date":298,"type":50},"2025-01-24",{"date":300,"type":21},"2025-02-01",{"date":302,"type":21},"2027-06-01",{"name":304,"class":90},"Chirec",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":58},"100552175","effectiveness-of-artificial-intelligence---assisted-colonoscopy-in-colorectal-neoplasms-100552175","NCT06469671","Effectiveness of Artificial Intelligence - Assisted Colonoscopy in Colorectal Neoplasms","Artificial Intelligence - Assisted Colonoscopy in Diagnosis of Colorectal Neoplasms: Russian Multicenter Randomised Open - Label Trial","ArtInCol","Inclusion Criteria:\n\n* Screening coloscopy is needed\n\nExclusion Criteria:\n\n* Indications for colonoscopy\n* Previously detected colorectal neoplasms\n* Previously performed colorectal surgery\n* Colorectal cancer\n* Inflammatory bowel disease","90 Years",{"count":315,"type":21},1000,[71],"The primary goal of this study is to estimate the effectiveness of a medical decision support system based on artificial intelligence in the endoscopic diagnosis of benign tumors.\n\nResearchers will compare Adenoma detection rate between \"artificial intelligence - assisted colonoscopy\" and \"conventional colonoscopy\" groups to evaluate the clinical effectiveness of artificial intelligence model.",[34,291,319],"Diagnosis","2024-06-17",{"date":322,"type":50},"2024-06-21",{"date":324,"type":21},"2024-07",{"date":326,"type":21},"2024-12",{"name":328,"class":225},"State Scientific Centre of Coloproctology, Russian Federation",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":283,"sex":16,"minAge":337,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100519315","artificial-intelligence-to-implement-cost-saving-strategies-for-colonoscopy-screening-based-on-in-vivo-prediction-of-polyp-histology-100519315","NCT06041945","Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology","Saving by Artificial Intelligence for Virtual Endoscopy Biopsy Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology","SAVE","Inclusion Criteria:\n\n* All \\>40 years-old patients undergoing colonoscopy for selected indications\n\nExclusion Criteria:\n\n* patients with personal history of CRC, or IBD\n* patients affected with Lynch syndrome or Familiar Adenomatous Polyposis.\n* patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale \\\u003C2 in any colonic segment).\n* patients with previous colonic resection.\n* patients on antithrombotic therapy, precluding polyp resection.\n* patients who were not able or refused to give informed written consent.","40 Years",{"count":339,"type":21},1800,[71],"This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of cost-saving strategies in screening programs. A cost-effectiveness analyses with the use of modern trial emulation analyses of large observational and clinical trial datasets and real-cost data will be conducted. To improve personalized treatment with a novel colonoscopy CADx risk-prediction tool, the investigators will even develop a novel deep learning algorithm for the optical biopsy of the alternative pathway of colorectal cancer carcinogenesis, namely the serrated pathway and develop cost-effectiveness models of AI-assisted optical biopsy in colorectal cancer screening that provides reliable information to identify cancer risk regardless of physicians' skill.",[34],"2023-10-03",{"date":345,"type":50},"2023-10-04",{"date":347,"type":50},"2023-09-21",{"date":349,"type":21},"2027-09-01",{"name":351,"class":90},"Istituto Clinico Humanitas",2]